CYP4A Antibody (E-6): sc-271983

CYP4A Antibody (E-6) is a mouse monoclonal IgG1 kappa light chain antibody that detects the CYP4A protein of mouse and rat origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). anti-CYP4A antibody (E-6) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. The CYP4A protein family plays a crucial role in the metabolism of fatty acids, particularly in the conversion of arachidonic acid into biologically active metabolites such as hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acid, which are essential for regulating blood pressure and mediating signaling pathways. Understanding the function of CYP4A proteins is vital, as CYP4A proteins are involved in the detoxification of xenobiotics and the metabolism of endogenous compounds, thereby influencing various physiological processes and potential disease states. The CYP4A family includes several murine proteins, such as CYP4A10, CYP4A12A, CYP4A12B, CYP4A14, CYP4A29, CYP4A31, CYP4A32, and CYP4A30B, which may exhibit distinct yet overlapping functions in fatty acid metabolism, highlighting CYP4A (E-6) antibody′s importance in research focused on metabolic pathways and pharmacological responses.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CYP4A Antibody (E-6) References:

1. Covalently linked heme in cytochrome p4504a fatty acid hydroxylases.  |  Hoch, U. and Ortiz De Montellano, PR. 2001. J Biol Chem. 276: 11339-46. PMID: 11139583
2. Arachidonate CYP hydroxylases of kidney contribute to formation of hypertension and maintenance of blood pressure.  |  Zhang, F., et al. 2002. Acta Pharmacol Sin. 23: 497-502. PMID: 12060522
3. Contribution of cytochrome P450 4A isoforms to renal functional response to inhibition of nitric oxide production in the rat.  |  Hercule, HC., et al. 2003. J Physiol. 551: 971-9. PMID: 12857783
4. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants.  |  Nelson, DR., et al. 2004. Pharmacogenetics. 14: 1-18. PMID: 15128046
5. Contribution of arachidonic acid metabolites derived via cytochrome P4504A to angiotensin II-induced neointimal growth.  |  Yaghini, FA., et al. 2005. Hypertension. 45: 1182-7. PMID: 15897359
6. Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha.  |  Ng, VY., et al. 2007. Drug Metab Dispos. 35: 1126-34. PMID: 17431031
7. Role of the CYP4A/20-HETE pathway in vascular dysfunction of the Dahl salt-sensitive rat.  |  Lukaszewicz, KM. and Lombard, JH. 2013. Clin Sci (Lond). 124: 695-700. PMID: 23438293
8. Inhibition of CYP4A reduces hepatic endoplasmic reticulum stress and features of diabetes in mice.  |  Park, EC., et al. 2014. Gastroenterology. 147: 860-9. PMID: 24983671
9. CYP4A in tumor-associated macrophages promotes pre-metastatic niche formation and metastasis.  |  Chen, XW., et al. 2017. Oncogene. 36: 5045-5057. PMID: 28481877
10. The role of SHP/REV-ERBα/CYP4A axis in the pathogenesis of alcohol-associated liver disease.  |  Yang, Z., et al. 2021. JCI Insight. 6: PMID: 34423788
11. Mechanism of the components compatibility of Scutellariae Radix and Coptidis Rhizoma on mice with hyperlipidemia by regulating the Cyp4a family.  |  Gao, Y., et al. 2024. J Ethnopharmacol. 331: 118263. PMID: 38677575
12. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature.  |  Nelson, DR., et al. 1996. Pharmacogenetics. 6: 1-42. PMID: 8845856

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CYP4A Antibody (E-6) has 18 citations in a variety of scientific publications.

Primary antibodies like Anti-CYP4A Antibody (E-6) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CYP4A Antibody (E-6) Specifications

Alternate Product Name: CYP4A

Product Clone Name: E-6

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 301-507

Epitope Target: CYP4A

Epitope Species: mouse

Product Reactivity/Detection: a broad range of CYP4A family members

Species Reactivity/Detection: mouse, rat

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 18 citations in various scientific publications

Available Conjugates/Forms for CYP4A Antibody (E-6): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin